CCRN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cross Country Healthcare Inc (CCRN) is not a strong buy for a beginner, long-term investor at this time. The stock is currently oversold with bearish technical indicators, weak financial performance, and no significant positive catalysts in the near term. While the company has potential upside due to its strategic pivot and clean balance sheet, the lack of immediate growth signals and negative sentiment from analysts suggest holding off on investment until clearer signs of recovery emerge.
The stock is showing bearish momentum with MACD negatively expanding (-0.109), RSI indicating oversold conditions (11.752), and moving averages in a bearish alignment (SMA_200 > SMA_20 > SMA_5). The price is near a key support level at S2: 7.643, but there is no indication of a reversal yet.
The company has a debt-free balance sheet with $119M liquidity, potential for share buybacks, and a strategic pivot to a tech-enabled staffing provider. Additionally, co-founder Kevin Clark's return as CEO brings expertise in technology platform development.
The failed Aya Healthcare merger has negatively impacted sentiment, with analysts lowering price targets. Financial performance in Q3 2025 showed significant declines in revenue (-20.65% YoY), net income (-286.85% YoY), and EPS (-287.50% YoY). Technical indicators remain bearish, and there is no immediate catalyst for recovery.
In Q3 2025, the company reported a revenue drop to $250.05M (-20.65% YoY), net income of -$4.77M (-286.85% YoY), and EPS of -$0.15 (-287.50% YoY). Gross margin also declined slightly to 18.73% (-1.06% YoY), reflecting weak financial performance.
Analyst sentiment is mixed to neutral. Wedbush initiated coverage with a Neutral rating and an $11 price target, citing potential upside if the company executes its tech-led transformation. Other firms have downgraded price targets following the failed merger, with targets ranging from $8.65 to $11. Citizens JMP upgraded the stock to Outperform, citing potential risk/reward below $8 and early signs of stabilization in the healthcare staffing industry.
